Unknown

Dataset Information

0

Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials.


ABSTRACT: Immunotherapeutic approaches are currently in the spotlight for their potential as disease-modifying treatments for neurodegenerative disorders. The discovery that ?-synuclein (?-syn) can transmit from cell to cell in a prion-like fashion suggests that immunization might be a viable option for the treatment of synucleinopathies. This possibility has been bolstered by the development of next-generation active vaccination technology with short peptides-AFFITOPEs(®) (AFF)- that do not elicit an ?-syn-specific T cell response. This approach allows for the production of long term, sustained, more specific, non-cross reacting antibodies suitable for the treatment of synucleinopathies, such as Parkinson's disease (PD). In this context, we screened a large library of peptides that mimic the C-terminus region of ?-syn and discovered a novel set of AFF that identified ?-syn oligomers. Next, the peptide that elicited the most specific response against ?-syn (AFF 1) was selected for immunizing two different transgenic (tg) mouse models of PD and Dementia with Lewy bodies, the PDGF- and the mThy1-?-syn tg mice. Vaccination with AFF 1 resulted in high antibody titers in CSF and plasma, which crossed into the CNS and recognized ?-syn aggregates. Active vaccination with AFF 1 resulted in decreased accumulation of ?-syn oligomers in axons and synapses, accompanied by reduced degeneration of TH fibers in the caudo-putamen nucleus and by improvements in motor and memory deficits in both in vivo models. Clearance of ?-syn involved activation of microglia and increased anti-inflammatory cytokine expression, further supporting the efficacy of this novel active vaccination approach for synucleinopathies.

SUBMITTER: Mandler M 

PROVIDER: S-EPMC4034750 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature

altmetric image

Publications

Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials.

Mandler Markus M   Valera Elvira E   Rockenstein Edward E   Weninger Harald H   Patrick Christina C   Adame Anthony A   Santic Radmila R   Meindl Stefanie S   Vigl Benjamin B   Smrzka Oskar O   Schneeberger Achim A   Mattner Frank F   Masliah Eliezer E  

Acta neuropathologica 20140214 6


Immunotherapeutic approaches are currently in the spotlight for their potential as disease-modifying treatments for neurodegenerative disorders. The discovery that α-synuclein (α-syn) can transmit from cell to cell in a prion-like fashion suggests that immunization might be a viable option for the treatment of synucleinopathies. This possibility has been bolstered by the development of next-generation active vaccination technology with short peptides-AFFITOPEs(®) (AFF)- that do not elicit an α-s  ...[more]

Similar Datasets

| S-EPMC4610034 | biostudies-literature
| S-EPMC7341790 | biostudies-literature
| S-EPMC6356731 | biostudies-literature
| S-EPMC9853228 | biostudies-literature
| S-EPMC4940024 | biostudies-literature
| S-EPMC9606184 | biostudies-literature
| S-EPMC10234769 | biostudies-literature
| S-EPMC3321268 | biostudies-other
2017-10-04 | PXD006484 | Pride
| S-EPMC4157468 | biostudies-other